Author

Yanli Xing

Virginia Commonwealth University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Anthony C. FaberiD· 1 shared Bin Hu· 1 shared Jamie M. Slaughter· 1 shared Jane Roberts· 1 shared Jennifer E. KoblinskiiD· 1 shared Konstantinos V. FlorosiD· 1 shared Krista M. DaltoniD· 1 shared Kun ZhangiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anthony C. FaberORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS-mutant neuroblastoma

Ronald D. Hill, Krista M. Dalton, Richard Kurupi, Jamie M. Slaughter, Jane Roberts, Yanli Xing, Victor Kehinde, Kun Zhang, Bin Hu, Vita Kraskauskiene, Madelyn R. Lorenz, Jennifer E. Koblinski, Mikhail G. Dozmorov, Konstantinos V. Floros, Anthony C. Faber

This study shows that Daraxonrasib (RMC-6236) effectively targets RAS-mutant neuroblastoma by inhibiting MAPK signaling and enhancing cell death.

bioRxiv · Feb 20, 2026 · PreprintCancer Biology